Subtypes of Venous Thromboembolism in Inflammatory Bowel Disease: A Nationwide Assessment.
Document Type
Article
Publication Date
3-5-2024
Publication Title
Clinical research and clinical trials
Abstract
BACKGROUND: Data detailing the risk of Venous Thromboembolism (VTE) subtypes among individuals with Inflammatory bowel disease (IBD) remain limited.
MATERIALS & METHODS: Using the Nationwide Inpatient Sample database, we applied a multivariable regression analysis to compare the odds of primary VTE-related hospitalizations among individuals with and without IBD from 2016 to 2020, including deep venous thrombosis (DVT), pulmonary embolism (PE), portal vein thrombosis (PVT), Budd Chiari syndrome (BCS), renal vein thrombosis (RVT), and cerebral venous sinus thrombosis (CVST).
RESULTS: Overall, there were 15,565 primary VTE-related hospitalizations among individuals with IBD, as compared to 1,449,164 among individuals without IBD. Having IBD increased the odds for DVT (aOR = 1.34, 95%CI: 1.25-1.43), PVT (aOR = 3.16, 95%CI: 2.65-3.76), and CVST (aOR=1.45, 95%CI: 1.05-2.00), without significant increase in the odds of a PE, BCS, or RVT. Further, individuals with ulcerative colitis (UC) were at a higher risk for the majority of VTE-subtypes as compared to those with Crohn's disease (CD). Among individuals with a VTE-related hospitalization, the presence of IBD was not associated with increased mortality (aOR = 0.77, 95%CI: 0.40-1.50), but was associated with an increased length of stay (CD - 4.8 days, UC - 5.3 days, without IBD - 4.3 days, p<0.01).
CONCLUSIONS: Clinicians should retain a high index of suspicion when evaluating VTE-related symptoms among individuals with IBD, as the presence of IBD confers a higher risk of DVT, PVT and CVST related-hospitalizations, and longer stays as compared to individuals without IBD.
Volume
9
Issue
3
First Page
186
Recommended Citation
Kilani Y, Aldiabat M, Lim CY, Kamal SAF, Puelo PC, Vohra A, et al Subtypes of venous thromboembolism in inflammatory bowel disease: a nationwide assessment. Clin Res Clin Trials. 2024;9(3):186. PMID: 38577383
ISSN
2693-4779
PubMed ID
38577383
